

THE SYNTHESIS OF L- α -AMINOADIPYL-L-CYSTEINYL-D-3,4-DIDEHYDRO-
VALINE, A POTENT INHIBITOR OF ISOPENICILLIN SYNTHETASE

JACK E. BALDWIN*, BULBUL CHAKRAVARTI, LESLIE D. FIELD,
JOHN A. MURPHY and KATHY R. WHITTEN

Dyson Perrins Laboratory, University of Oxford,
South Parks Road, Oxford, OX1 3QY, U.K.




and

SIR EDWARD P. ABRAHAM* and GAMINI JAYATILAKE
Sir William Dunn School of Pathology, University of
Oxford, South Parks Road, Oxford, OX1 3RE, U.K.

(Received in U.K. 23 July 1982)


Abstract - The title peptide (1) has been synthesized and incubated with an active cell-free extract of *Cephalosporium acremonium*, no conversion to active antibiotics was observed; however on co-incubation with the Arnstein tripeptide (ACV) (2), strong inhibition of the conversion of ACV to isopenicillin N was observed.

It is well established that the peptide (2) is efficiently converted into isopenicillin N by cell-free extracts of *C. acremonium*. The nature of the conversion has aroused much interest¹. Little is known of the active site on the enzyme complex which effects this conversion. In order to probe the chemical properties of the active site, we have synthesised the unnatural tripeptide (1) and have tested it for conversion to antibiotics. We have also co-incubated this peptide with the natural substrate (2) to observe if conversion of (2) to isopenicillin N is inhibited. Recently, Neuss *et al*² have isolated a tripeptide containing the 3,4-didehydrovaline moiety viz. α -aminoadipylserinyl-3,4-didehydrovaline (3) from the broth of *Penicillium chrysogenum*. This heightened our interest in the synthesis of the tripeptide (1) and in the testing of its effect on isopenicillin N synthetase.



Thus penicillin N benzyl ester (4) was oxidized to the sulphoxide (5) 85%. This was converted to the thiazoline (6), 72%, by heating under reflux in benzene in the presence of trimethyl phosphite. The thiazoline was cleaved to the mercury salt (7), 66% which was coupled with N-benzyloxy-carbonyl-L- α -aminoadipic acid α -benzyl ester³ to yield the salt (8). (8)

was converted directly to the thiol (9) (by treatment with H_2S and $NaBH_3CN$) isolated as its S-acetyl derivative (10) (Ac_2O , pyridine), 24% from (7). The crystalline thiol ester was cleanly converted to the peptide (1) and an equivalent of acetamide by treatment with sodium in liquid ammonia at $-78^\circ C$. Attempts to separate the peptide from the inorganic salts formed during work up of the deprotection reaction and from acetamide by the standard techniques (treatment with Hopkin's reagent or chromatography on Biogel P2, or preparative electrophoresis or reverse phase HPLC) led to decomposition of the peptide as witnessed by nmr and analytical electrophoresis.



When the tripeptide (1) was incubated as detailed in the experimental section with a cell-free extract of *C. acremonium* no disappearance of (1) could be detected by 1H nmr spectroscopy⁴. In the incubation mixture, no antibiotic activity could be detected by hole-plate assay⁵ against *Staphalococcus aureus*.

When the tripeptide 1 (0.25 equiv)

and ACV 2 (1 equiv) were co-incubated with a cell-free extract of *C. acremonium* the initial rate of production of isopenicillin N was reduced by a factor of 3.2 compared to a control incubation containing no inhibitor.

EXPERIMENTAL

General Procedures

All solvents were distilled prior to use. Dichloromethane was dried by distillation from calcium hydride. Benzene was dried by distillation from sodium. 2,2-dimethylpropan-1,3-diol was purified by recrystallisation from benzene. Trimethyl phosphite and benzyl bromide were purified by distillation just prior to use.

Nmr spectra were measured on a Bruker WH 300 spectrometer. Spectra were taken in deuteriochloroform unless otherwise stated. Mass spectra were obtained using VG Micromass ZAB 1F and 16F instruments. Optical rotations were measured on a Perkin-Elmer 241 polarimeter. Infra-red spectra were determined on a Perkin-Elmer 257 spectrometer. TLC was carried out using glass-supported silica gel 60 plates. Preparative chromatography was carried out using Merck Silica Gel 60.

Penicillin V benzyl ester (4)

A mixture of freshly dried DMF (100 ml), potassium salt of penicillin V (19.40 g, 0.05 mole) and benzyl bromide (8.545 g, 0.05 mole) was stirred under nitrogen for 24 h at room temperature. The reaction mixture was filtered, poured into water (250 ml) and extracted with dichloromethane (4 x 80 ml). The combined extracts were washed with water (10 x 60 ml), dried over sodium sulphate, and the solvent removed *in vacuo* to yield a yellow oil which was crystallised by dissolving it in chloroform and adding petrol ether ($40^\circ-60^\circ C$). The ester 4, was obtained as a white solid (20.94 g, 95%) m.pt. $70-72^\circ C$ δ^1H 1.43 (3H, s, CH_3-C-S-), 1.58 (3H, s, CH_3-C-S-), 4.36 (2H, q, $J = 15.2Hz$, $-O-CH_2-$), 4.58 (1H, s, $-CH-CMe_2S-$), 5.20 (2H, s, $-CH_2O-$), 5.59 (1H, d, $J = 4.2Hz$, H-7), 5.75 (1H, dd, $J = 9.2, 4.2 Hz$, H-6), 6.92-7.30 (11H, m, ArH + NH); ν_{max} (CHCl₃) 3415, 3035, 3015, 1785, 1745, 1690, 1600, 1580, 1540, 1495, cm^{-1} ; λ (MeOH), 261, 267, 274; m/e 440 (M^+); $[\alpha]_D^{20} = 130^\circ$ ($c = 0.32$, CHCl₃).

Penicillin V sulphoxide benzyl ester (5)

Penicillin V benzyl ester (4, 20.42 g, 0.046 mole) was dissolved in dry dichloromethane (200 ml) and the solution was cooled to 5°C. A solution of m-chloroperbenzoic acid (8.396 g, 0.0487 mole) in dry dichloromethane was added with stirring over 30 min and the reaction was stirred for a further 30 min at 10°C. The solution was washed with a saturated solution of sodium hydrogen carbonate then with brine. The solution was dried over sodium sulphate, and the solvent removed in vacuo to give a white foam, which was crystallised from dichloromethane/diethyl ether. Penicillin V sulphoxide benzylester (5) was obtained as a white solid (18.106 g, 85%) m.pt. 125°C (lit⁶ 124-125°C), $\delta^1\text{H}$ 1.077 (3H, s, $\text{CH}_3\text{-C-S-}$), 1.68 (3H, s, $\text{CH}_3\text{-C-S-}$), 4.53 (2H, s, $-\text{CH}_2\text{-O-}$), 4.70 (1H, s, $-\text{CH-CMe}_2\text{-S-}$), 5.02 (1H, d, J = 4.8 Hz, H-7), 5.23 (2H, q, J = 11.9 Hz, $-\text{CH}_2\text{-O-}$), 6.10 (1H, dd, J = 10.5, 4.6 Hz, H-6), 6.91 to 7.38 (10H, m, ArH), 8.25 (1H, d, J = 10.5 Hz, NH); ν_{max} (CHCl_3) 3380, 3010, 1800, 1740, 1690, 1600, 1515, 1490, cm^{-1} ; λ_{max} (MeOH) 267, 273 nm, m/e 456 (M^+), 458, $[\alpha]_{\text{D}}^{20} + 169^\circ$ (c = 0.58, CHCl_3). D

4,7-diaza-7-(1-benzyloxycarbonyl-2-methylprop-2-enyl)-3-phenoxymethyl-2-thiabicyclo-[3.2.0]-hept-3-en-6-one (6)

The penicillin sulphoxide (5, 4.41 g, 9.66 mmole), dry benzene (72.5 ml) and trimethyl phosphite (1.14 ml, 1.20 g, 9.66 mmole) were heated for 15 h under reflux with a Dean-Stark attachment. The mixture was cooled and evaporated to leave an orange oil which was purified by column chromatography (1:1, ethyl acetate: hexane) to give the desired thiazoline (6) as white needles (2.945 g, 72%) m.pt. 55-57.5°C; $\delta^1\text{H}$ 1.73 (3H, s, $-\text{CH}_3$), 4.91 (2H, dq, J = 14.2, 1.2 Hz, O-CH_2), 4.87 (2H, s, $-\text{C}=\text{CH}_2$), 5.05 (1H, s, $-\text{CH-CMe}_2\text{-}$), 5.18 (2H, q, J = 12.2 Hz, O-CH_2), 5.91 (1H, d, J = 4.3 Hz, $-\text{S-CH-N-}$), 6.00 (1H, dt, J = 4.3, 1.2 Hz, H-5), 6.90-7.38 (10H, m); ν_{max} 3030, 3010, 1770, 1740, 1650, 1620, 1600, 1580, 1495, 1240, 1160, m/e 422 (M^+) $[\alpha]_{\text{D}}^{20} -124^\circ$ (c = 0.58, CHCl_3). Found: C, 65.17%, H, 5.23%, N, 6.71%; $\text{C}_{23}\text{H}_{22}\text{N}_2\text{O}_4\text{S}$ requires: C, 65.40%, H, 5.21%, N, 6.63%.

Preparation of 3-amino-1-(1-benzyloxycarbonyl-2-methylprop-2-enyl)-4-thiomercury (II) chlorid-azetidin-2-one hydrochloride salt (7)

The thiazoline (6, 0.200 g, 0.47 mmole) was dissolved in dry dichloromethane (2 ml) in a dry nitrogen atmosphere. Mercuric chloride (0.128 g, 0.47 mmole) and 2,2-dimethylpropan-1,3-diol (0.049 g) were added in one lot. After stirring for 14 h, the fine white precipitate was filtered and washed with dichloromethane, then dried to give the desired hydrochloride salt

(7, 0.182 g, 66%) m.pt. 158-163°C, $\delta^1\text{H}$ (d_6 -DMSO) 1.82 (3H, s, CH_3), 4.70 (1H, d, J = 4.7 Hz, H-4), 4.86 (1H, s, $-\text{CH-CMe}_2\text{-}$), 5.04 and 5.09 (2H, 2 x s, $-\text{C}=\text{CH}_2$), 5.20 (2H, q, J = 12.4 Hz, $-\text{OCH}_2$), 5.70 (1H, d, J = 4.7 Hz, H-5), 7.3-7.5 (5H, m, ArH), 8.70 (3H, br. s, RN^+H_3); λ_{max} 206 nm, m/e: 561 (M^+) Found: C, 30.9%, H, 3.4%, N, 4.8%; $\text{C}_{15}\text{H}_{18}\text{Cl}_2\text{HgN}_2\text{O}_3\text{S}$ requires: C, 31.2%, H, 3.1%, N, 4.8%

N-benzyloxycarbonyl- α -benzyl- δ -(L- α -aminoadipyl)-S-acetyl-L-cysteinyl-D-3,4-didehydrovaline benzyl ester (10)

The amine hydrochloride (7, 0.58 g, 1.00 mole) was added to dichloromethane (100 ml) and the suspension was washed with saturated sodium hydrogen carbonate solution under nitrogen. The organic phase was dried over sodium sulphate, filtered and concentrated to approximately 30 mls then added, under nitrogen, to a solution of N-carbethoxy-2-ethoxy-1,2-dihydroquinoline (EEDQ, 0.256 g, 1.04 mmole) and N-benzyloxycarbonyl-L- α -aminoadipic acid α -benzyl ester (0.38 g, 0.987 mmole) in dichloromethane. After stirring for 3 days, the mixture was diluted with dichloromethane, washed in turn with 2N hydrochloric acid, saturated sodium carbonate solution and water. The solution was dried over sodium sulphate, filtered and the solvent removed in vacuo to yield a yellow foam. [If desired this material could be purified at this stage by chromatography on silica gel using i) 1 CH_2Cl_2 : 9 EtOAc and ii) 5 CH_2Cl_2 : 5 EtOAc. The resulting white foam had a ^1H nmr spectrum consistent with the thiomercuric chloride (8)]. Routinely, crude 8 was used directly without further purification. Crude 8 (0.15 g) was added to freshly dried methane (20 mls), distilled from magnesium methoxide) under nitrogen. Hydrogen sulphide was vigorously bubbled through the suspension for 10 minutes at 0°C and the resulting slurry was filtered through Celite under nitrogen. Acetic acid (2 ml) was added to the filtrate and then a solution of sodium cyanoborohydride (0.200 g) in dry methanol (10 ml) was added dropwise over 10 mins. After 1 h, the solvent was removed in vacuo to leave a white foam. Acetic anhydride (2 ml) was added under nitrogen followed by pyridine (0.2 ml) and the mixture was stirred for 1.5 h, then washed with 2N hydrochloric acid. The organic solution was dried over sodium sulphate filtered and the solvent removed in vacuo. The residue was purified by column chromatography (i) 7 CHCl_3 : 3 EtOAc; ii) 5 CH_2Cl_2 : 5 EtOAc to yield pure protected tripeptide (10) as white prisms (28.3 mg, 24% from 7) m.pt. 133-134°C, $\delta^1\text{H}$ 1.73 (3H, s, CH_3), 1.58-1.74 (4H, m, $-\text{COCH}_2\text{-CH}_2\text{-CH}_2\text{-}$), 2.16-2.25 (2H, m, $-\text{COCH}_2\text{-CH}_2\text{-}$), 2.35 (3H, s, $\text{CH}_2\text{CCS-}$), 3.26 (2H, m, $-\text{CH}_2\text{S-}$), 4.41 (1H, m, $-\text{N-CH-CO-}$), 4.59 (1H, m, $-\text{N-CH-CO-}$), 4.95-

5.18 (9H, m, 3 x -OCH₂Ph, -CH-CMeCH₂),
 5.63 (1H, d, J = 9.0 Hz, NH), 6.44
 (1H, d, J = 7.1 Hz, NH), 7.29-7.40
 (m, 15H, Ar-H); ν (CH₂Cl₂) 3420, 1740,
 1730, 1690, m/e 717 (M⁺); Found: 717.
 2737: C₃₈H₄₃N₂O₉S requires 717.2720.
 Found: C, 63.37%, H, 5.97%, N, 6.01%,
 C₃₈H₄₃N₂O₉S Requires: C 63.58%,
 H, 6.07%, N, 5.85%, $[\alpha]_D^{20}$ -40.7°
 (c = 1.3, CHCl₃).

Preparation of δ -(L- α -aminoadipyl)-L-
 cysteinyl-D-3,4-didehydrovaline (1)

Ammonia (10 mls) was distilled
 onto the protected peptide (10 8.4 mg),
 at -78°C under an argon atmosphere.
 Sodium metal was added in small amounts
 until a permanent blue colour developed
 in the solution. Ammonium sulphate
 was added until the blue colour faded
 and the ammonia was evaporated. The
 residue was brought to pH 2.0 with
 0.05M sulphuric acid and then back to
 pH 6.85 with 3N sodium hydrogen
 carbonate solution. The product
 was then freeze dried. The total
 solid weight after freeze drying was
 0.367 g containing 4.23 mg of the
 tripeptide (1). The ¹H nmr spectrum
 of the product was clearly consistent
 with the desired peptide plus one
 equivalent of acetamide. δ^H (D₂O)
 1.51 (3H, s, CH₃C = CH₂), 1.41-1.70
 (4H, m, -CH₂CH₂CH₂CO-), 1.80 (3H, s,
 acetamide), 2.24 (2H, t, J = 7.4 Hz,
 -CH₂CO-), 2.72 (2H, m, -CH₂S-), 3.55
 (1H, t, J = 5.9 Hz, -COCHNH-), 4.35
 (1H, t, J = 5.5 Hz -COCHNH-), 4.45
 (1H, s, CH₂=CMeCH-), 4.83 (2H, br.s.,
 MeC = CH₂).

Electrophoresis was performed
 on the product at pH 4.5 (4kv, 1 hour).
 This afforded a single mobile zone
 sensitive to cadmium/ninhydrin.
 The zone gave a positive reaction with
 a thiol-active spray.

Incubation of peptide 1 with cell-free
 extract of *C. acremonium*

(a) Production of β -lactam antibiotics

The tripeptide L- α -aminoadipyl-L-
 cysteinyl-D-3,4-didehydrovaline
 (initial concentration 3mM) was
 incubated for 12 h at 20°C with a
 cell-free extract of *C. acremonium* in
 the presence of dithiothreitol (10 mM),
 L-ascorbate (750 μ M), Fe²⁺ (75 μ M) and
 bovine liver catalase (10000 units/ml)
 in an ammonium hydrogen carbonate
 buffer at pH 8.1 (50 mM). No
 disappearance of ACD could be detected
 by ¹H nmr spectroscopy, and no anti-
 biotic activity could be detected by
 hole-plate assay against *S. aureus*.

(b) Inhibition of the conversion of
 ACV to isopenicillin N

The tripeptide ACD (initial
 concentration 0.75 mM) and ACV (initial
 concentration 3 mM) were co-incubated
 with a cell-free extract of *C. acremonium*
 at 20°C in the presence of the cofactors
 and buffer (as described above). The
 rate of conversion of ACV to

isopenicillin N was measured directly⁴
 by ¹H nmr spectroscopy by monitoring
 the disappearance of the valinyl-methyl
 resonances of ACV (80.97, 81.02 ppm)
 and the appearance of the α - and β -
 methyl resonances of isopenicillin N
 (81.62, 81.74) in aliquots taken
 as the incubation progressed. The
 rate of production of isopenicillin N
 was reduced by a factor of 3.2 relative
 to a control incubation containing no
 ACD. The inorganic salt and acetamide
 which arise during the deprotection of
 the tripeptide were shown to have
 no effect on the rate of production of
 isopenicillin N in a separate control
 experiment.

We thank the SERC and the Sir
 E P Abraham cephalosporin fund for
 financial support.

References

- 1 J.O'Sullivan, R.C. Bleaney, J.A.
 Huddleston and E.P. Abraham,
Biochem.J. 1980, **184**, 421;
 T. Konomi, S. Herchen, J.E. Baldwin,
 M. Yoshida, N.A. Hunt and A.L.
 Demain, *ibid*, 1980, **184**, 427;
 P.A. Fawcett, J.J. Usher, J.A.
 Huddleston, R.C. Bleaney, J.J. Nisbet
 and E.P. Abraham, *ibid*, 1976, **157**,
 651; J.E. Baldwin, B.L. Johnson,
 J.J. Usher, E.P. Abraham, J.A.
 Huddleston and R.L. White, *J.Chem.*
Soc.Chem.Commun. 1980, 1271.
- 2 N. Neuss, R.D. Miller, C.A. Affolder,
 W. Nakatsukasa, J. Mabe, L.L.
 Huckstep, N. De La Higuera, A.H.
 Hunt, J.L. Occolowitz and J.H.
 Gilliam, *Helv.Chim.Acta* 1980,
63, 1119.
- 3 J.E. Baldwin, P. Harrison and J.A.
 Murphy, *J.Chem.Soc.Chem.Commun.*
 in press.
- 4 G. Bahadur, J.E. Baldwin, L.D. Field,
 E-M.M. Lehtonen, J.J. Usher, C.A.
 Vallejo, E.P. Abraham and R.L. White
J.Chem.Soc.Chem.Commun. 1982, 917;
 R.M. Adlington, R.P. Aplin, J.E.
 Baldwin, L.D. Field, E-M.M. John,
 E.P. Abraham and R.L. White, *J.Chem.*
Soc.Chem.Commun. 1982, 137; R.M.
 Adlington, R.T. Aplin, J.E. Baldwin,
 L. D. Field, E-M.M. John, E.P.
 Abraham, R.L. White and B. Chakravarti,
J.Amer.Chem.Soc., submitted for
 publication.
- 5 E.P. Abraham, J.A. Huddleston, G.S.
 Jayatilake, J.O'Sullivan and
 R.L. White in "Recent Advances in
 the Chemistry of β -Lactam Anti-
 biotics" 2nd international
 symposium, G.I. Gregory (ed),
 Special Publication of the
 Chemical Society, 1981, 125.
- 6 A.W. Chow, N.H. Hall and J.R.E.
 Hoover, *J.Org.Chem.* 1962, **27**, 1381.
- 7 P.H.A. Sneath and J.F. Collins,
Biochem.J. 1961, **79**, 512.